Pioneering cancer therapy makes two CAR-T drugs the approvals of the year

T

his biopharma superlative is a no-brainer: The most noteworthy drug approval of the year goes, hands-down, to the two CAR-T drugs that hit the market earlier this year.

Kymriah, from Novartis (NVS), was approved in late August, with a price tag set at $475,000. And Yescarta, developed by Kite Pharma and acquired by Gilead Sciences (GILD), was approved in October, with a $373,000 set price. Both work with just a single infusion.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

What is STAT Plus?

About the Author

Meghana Keshavan

Biotech Correspondent

Meghana covers biotech and writes The Readout newsletter.

Meghana.Keshavan@statnews.com

@megkesh

Tags

biotechnology

cancer

drug development

drug pricing

STAT Plus